Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy

Pharmacogenomics

Volumn 12, Issue 2, 2011, Pages 267-275

  Rosenstein, Barry S ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

genome wide association studies; personalized medicine; radiogenomics; radiotherapy

Indexed keywords

ATM PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE TRANSFERASE P1; MANGANESE SUPEROXIDE DISMUTASE; POLO LIKE KINASE; POLO LIKE KINASE 4; PROTEIN MDM2; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; XRCC1 PROTEIN; XRCC3 PROTEIN;

ARTICLE; BLADDER DISEASE; BREAST CANCER; BREAST FIBROSIS; CANCER PATIENT; CANCER RADIOTHERAPY; COPY NUMBER VARIATION; CYSTITIS; DISEASE PREDISPOSITION; DYSPHASIA; ERECTILE DYSFUNCTION; GENETIC VARIABILITY; GENOME ANALYSIS; GENOMICS; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LUNG FIBROSIS; ONCOLOGY; PERSONALIZED MEDICINE; PREDICTION; PROCTITIS; PROSTATE CANCER; RADIATION INJURY; RADIATION PNEUMONIA; RADIOGENOMICS; RADIOSENSITIVITY; RECTUM HEMORRHAGE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TOXICITY; TELANGIECTASIA;

GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RADIATION INJURIES; RADIATION TOLERANCE; RADIOTHERAPY;

EID: 79951883907     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.186     Document Type: Article

References (62)

1. Bentzen SM, Constine LS, Deasy JO: Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Int. J. Radiat. Oncol. Biol. Phys. 76(Suppl. 3), S3-S9 (2010).
2. Safwat A, Bentzen SM, Turesson I, Hendry JH: Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 52(1), 198-204 (2002). Study that provides evidence of inherent differences in radiosensitivity between individuals as well as evidence that genetic factors may play a role in accounting for this heterogenity in radiation response.
3. Begg AC, Russell NS, Knaken H, Lebesque JV: Lack of correlation of human fibroblast radiosensitivity in vitro with early skin reactions in patients undergoing radiotherapy. Int. J. Radiat. Biol. 64(4), 393-405 (1993).
4. Ozsahin M, Crompton NE, Gourgou S et al.: CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients. Clin. Cancer. Res. 11(20), 7426-7433 (2005).
5. Rodningen OK, Borresen-Dale AL, Alsner J et al.: Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis. Radiother. Oncol. 86(3), 314-320 (2008).
6. Bentzen SM, Parliament M, Deasy JO et al.: Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects. Int. J. Radiat. Oncol. Biol. Phys. 76(Suppl. 3), S145-S150 (2010). Review that stresses the importance of integrating biomarkers with dosimetry.
7. Popanda O, Marquardt JU, Chang-Claude J, Schmezer P: Genetic variation in normal tissue toxicity induced by ionizing radiation. Mutat. Res. 667(1-2), 58-69 (2009).
8. Barnett GC, West CM, Dunning AM: Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat. Rev. Cancer 9(2), 134-142 (2009).
9. Andreassen CN, Alsner J: Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. Radiother. Oncol. 92(3), 299-309 (2009).
10. Parliament MB, Murray D.: Single nucleotide polymorphisms of DNA repair genes as predictors of radioresponse. Semin. Radiat. Oncol. 20(4), 232-240 (2010).
11. Hall EJ, Schiff PB, Hanks GE: A preliminary report: frequency of A-T heterozygotes among prostate cancer patients with severe late responses to radiation therapy. Cancer J. Sci. Am. 4(6), 385-389 (1998).
12. Cesaretti JA, Stock RG, Atencio DP: A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 68(5), 1410-1416 (2007).
13. Cesaretti JA, Stock RG, Lehrer S: ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 61(1), 196-202 (2005).
14. Meyer A, Wilhelm B, Dork T: ATM missense variant P1054R predisposes to prostate cancer. Radiother. Oncol. 83(3), 283-288 (2007).
15. Damaraju S, Murray D, Dufour J et al.: Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin. Cancer Res. 12(8), 2545-2554 (2006).
16. Pugh TJ, Keyes M, Barclay L et al.: Sequence variant discovery in DNA repair genes from radiosensitive and radiotolerant prostate brachytherapy patients. Clin. Cancer. Res. 15(15), 5008-5016 (2009).
17. Peters CA, Stock RG, Cesaretti JA: TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 70(3), 752-759 (2007).
18. Burri RJ, Stock RG, Cesaretti JA et al.: Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat. Res. 170(1), 49-59 (2008).
19. Suga T, Iwakawa M, Tsuji H et al.: Influence of multiple genetic polymorphisms on genitourinary morbidity after carbon ion radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 72(3), 808-813 (2008).
20. Iannuzzi CM, Atencio DP, Green S et al.: ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int. J. Radiat. Oncol. Biol. Phys. 52(3), 606-613 (2002).
21. Alsner J, Rodningen OK, Overgaard J: Differential gene expression before and after ionizing radiation of subcutaneous fibroblasts identifies breast cancer patients resistant to radiation-induced fibrosis. Radiother. Oncol. 83(3), 261-266 (2007).
22. Bremer M, Klopper K, Yamini P et al.: Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: no observation of increased radiation-induced acute or late effects. Radiother. Oncol. 69(2), 155-160 (2003).
23. Edvardsen H, Tefre T, Jansen L et al.: Linkage disequilibrium pattern of the ATM gene in breast cancer patients and controls; association of SNPs and haplotypes to radio-sensitivity and post-lumpectomy local recurrence. Radiat. Oncol. 2, 25 (2007).
24. Andreassen CN, Alsner J, Overgaard M, Overgaard J: Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother. Oncol. 69(2), 127-135 (2003).
25. Andreassen CN, Alsner J, Overgaard J et al.: TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother. Oncol. 75(1), 18-21 (2005).
26. Andreassen CN, Overgaard J, Alsner J et al.: ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 64(3), 776-783 (2006).
27. Andreassen CN, Alsner J, Overgaard M et al.: Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM - a study based on DNA from formalin fixed paraffin embedded tissue samples. Int. J. Radiat. Biol. 82(8), 577-586 (2006).
28. Barnett GC, Coles CE, Burnet NG et al.: No association between SNPs regulating TGF-β1 secretion and late radiotherapy toxicity to the breast: results from the RAPPER study. Radiother. Oncol. 97(1), 9-14 (2010).
29. Popanda O, Tan XL, Ambrosone CB et al.: Genetic polymorphisms in the DNA double-strand break repair genes XRCC3, XRCC2, and NBS1 are not associated with acute side effects of radiotherapy in breast cancer patients. Cancer Epidemiol. Biomarkers Prev. 15(5), 1048-1050 (2006).
30. Angele S, Romestaing P, Moullan N et al.: ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res. 63(24), 8717-8725 (2003).
31. Giotopoulos G, Symonds RP, Foweraker K et al.: The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes. Br. J. Cancer. 96(6), 1001-1007 (2007).
32. Chang-Claude J, Popanda O, Tan XL et al.: Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin. Cancer. Res. 11(13), 4802-4809 (2005).
33. Ahn J, Ambrosone CB, Kanetsky PA et al.: Polymorphisms in genes related to oxidative stress (CAT, MnSOD, MPO, and eNOS) and acute toxicities from radiation therapy following lumpectomy for breast cancer. Clin. Cancer Res. 12(23), 7063-7070 (2006).
34. Ambrosone CB, Tian C, Ahn J et al.: Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: a case-series study. Breast Cancer Res. 8(4), R40 (2006).
35. Tan XL, Popanda O, Ambrosone CB et al.: Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. Breast Cancer Res. Treat. 97(3), 255-262 (2006).
36. Kuptsova N, Chang-Claude J, Kropp S et al.: Genetic predictors of long-term toxicities after radiation therapy for breast cancer. Int. J. Cancer. 122(6), 1333-1339 (2008).
37. Chang-Claude J, Ambrosone CB, Lilla C et al.: Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Br. J. Cancer. 100(10), 1680-1686 (2009).
38. Mangoni M, Bisanzi S, Carozzi F et al. Association between genetic polymorphisms in the XRCC1, XRCC3, XPD, GSTM1, GSTT1, MSH2, MLH1, MSH3, and MGMT genes and radiosensitivity in breast cancer patients. Int. J. Radiat. Oncol. Biol. Phys. (2010) (Epub ahead of print).
39. Suga T, Ishikawa A, Kohda M et al.: Haplotype-based ana lysis of genes associated with risk of adverse skin reactions after radiotherapy in breast cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 69(3), 685-693 (2007).
40. Isomura M, Oya N, Tachiiri S et al.: IL12RB2 and ABCA1 genes are associated with susceptibility to radiation dermatitis. Clin. Cancer Res. 14(20), 6683-6689 (2008).
41. Alsbeih G, Al-Harbi N, Al-Hadyan K et al.: Association between normal tissue complications after radiotherapy and polymorphic variations in TGFB1 and XRCC1 genes. Radiat. Res. 173(4), 505-511 (2010).
42. Lundberg M, Saarilahti K, Makitie AA, Mattila PS: TGFb1 genetic polymorphism is associated with survival in head and neck squamous cell carcinoma independent of the severity of chemoradiotherapy induced mucositis. Oral Oncol. 46(5), 369-372 (2010).
43. Tu HF, Chen HW, Kao SY et al.: MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. Radiother. Oncol. 87(2), 243-252 (2008).
44. Yuan X, Liao Z, Liu Z et al.: Single nucleotide polymorphism at rs1982073:T869C of the TGF{β}1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J. Clin. Oncol. 27(20), 3370-3378 (2009).
45. Hildebrandt MA, Komaki R, Liao Z et al.: Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One 5(8), (2010).
46. Zhang L, Yang M, Bi N et al.: ATM polymorphisms are associated with risk of radiation-induced pneumonitis. Int. J. Radiat. Oncol. Biol. Phys. 77(5), 1360-1368 (2010).
47. Bi N, Yang M, Zhang L et al.: Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer. Clin. Cancer Res. 16(8), 2383-2390 (2010).
48. Sun Z, Chen J, Aakre J et al.: Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients. Ann. Oncol. 21(10), 2011-2016 (2010).
49. De Ruyck K, Van Eijkeren M, Claes K et al.: Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. Int. J. Radiat. Oncol. Biol. Phys. 62(4), 1140-1149 (2005).
50. De Ruyck K, Van Eijkeren M, Claes K et al.: TGFβ1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. Int. J. Radiat. Oncol. Biol. Phys. 65(4), 1240-1248 (2006).
51. Severin DM, Leong T, Cassidy B et al.: Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitive cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 50(5), 1323-1331 (2001).
52. Thyagarajan B, Lindgren B, Basu S et al.: Association between genetic variants in the base excision repair pathway and outcomes after hematopoietic cell transplantations. Biol. Blood Marrow Transplant. 16(8), 1084-1089 (2010).
53. Fogarty GB, Muddle R, Sprung CN et al.: Unexpectedly severe acute radiotherapy side effects are associated with single nucleotide polymorphisms of the melanocortin-1 receptor. Int. J. Radiat. Oncol. Biol. Phys. 77(5), 1486-1492 (2010).
54. Azria D, Ozsahin M, Kramar A et al.: Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin. Cancer Res. 14(19), 6284-6288 (2008).
55. Kerns SL, Ostrer H, Stock R et al. Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 78(5), 1292-12300 (2010). First genome-wide association study to identify SNPs associated with a form of normal tissue toxicity in cancer patients treated with radiotherapy.
56. Niu N, Qin Y, Fridley BL et al.: Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res. 20(11), 1482-1492 (2010).
57. West C, Rosenstein BS: Establishment of a radiogenomics consortium. Radiother. Oncol. 94(1), 117-118 (2010). Announcement of the formation of the Radiogenomics Consortium that describes the rationale for its creation and its goals.
58. West C, Rosenstein BS, Alsner J et al.: Establishment of a Radiogenomics Consortium. Int. J. Radiat. Oncol. Biol. Phys. 76(5), 1295-1296 (2010).
59. Ho A, Fan G, Atencio D et al.: Possession of ATM sequence variants as a predictor for late normal tissue responses in breast cancer patients treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 69(3), 677-684 (2007).
60. Quarmby S, Fakhoury H, Levine E et al.: Association of transforming growth factor b-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int. J. Radiat. Biol. 79(2), 137-143 (2003).
61. Moullan N, Cox DG, Angele S et al.: Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol. Biomarkers Prev. 12(11 Pt 1), 1168-1174 (2003).
62. Werbrouck J, De Ruyck K, Duprez F et al.: Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int. J. Radiat. Oncol. Biol. Phys. 73(4), 1187-1195 (2009).